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Objective: To investigate the effects of a matrix metalloproteinase (MMP) inhibitor on joint pathology and
pain behavior in the rat meniscal transection (MNX) model of osteoarthritis (OA) and evaluate which
aspects of structural disease modiﬁcation contribute to symptom improvement.
Methods: OA pathology was induced in male Lewis rats, by transecting the medial collateral ligament with
(MNX) orwithout (SHAM) a full thickness cut through themeniscus. MNX animalswere orally administered
an equipotent MMP 2, 8, 9, 12, 13 inhibitor (0.25, 1 and 5 mg/kg/day) or vehicle from day 1. Chondropathy,
osteophytosis, osteochondral vascularity were assessed from toluidine blue stained coronal sections of the
total knee joint and weight-bearing asymmetry by incapacitance. Group differences were evaluated using
1-way analysis of variance (ANOVA) and associations as Spearman’s correlation coefﬁcients.
Results: Treatment with the MMP inhibitor reduced weight-bearing asymmetry from day 14 onwards,
and attenuated chondropathy (both P< 0.05). Osteochondral vascularity was elevated in MNX compared
with SHAM-operated animals (P< 0.001) and reduced, dose-dependently, by MMP inhibitor treatment
(r¼0.89, P< 0.05). Reduced osteochondral vascularity and chondropathy were associated with the
amelioration of weight-bearing asymmetry (both P< 0.05).
Conclusion: Here we show that treatment with a MMP inhibitor reduces joint damage, osteochondral
angiogenesis and behavioral evidence of pain. The association between osteochondral angiogenesis and
pain behavior may be explained by perivascular nerve growth or stimulation of subchondral nerves
following loss of osteochondral integrity. Our data suggest that targeting angiogenesis may have utility in
the treatment of pain associated with structural damage in OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license. Introduction
Osteoarthritis (OA) is a chronic and progressive disorder of the
joints that is widely thought of as primarily affecting the cartilage
with some bone changes. However, some authors have hypothe-
sized that the primary disorder is in the subchondral vasculature
and that the changes in the cartilage and osteophyte generation are
secondary phenomena1. Normal adult human cartilage is both
avascular2 and insensate3. Angiogenesis occurs at the osteochon-
dral junction in OA4, where vascular channels breach the tide-
mark5,6 and contain sympathetic and sensory nerves7,8. These
ﬁndings lead to the hypothesis that angiogenesis facilitates inner-
vation of articular cartilage, and therefore may be an importantto: Paul I. Mapp, Academic
al, Nottingham, NG5 1PB, UK.
Mapp).
ernational. Published by Elsevier Lstructural change that leads to pain. Matrix metalloproteinases
(MMPs) are known to degrade the cartilage9 and therefore they
may have a role in the ingrowth of blood vessels and nerves during
the initiation of OA. We hypothesized that inhibition of MMPs
would reduce pain behavior in OA by inhibiting osteochondral
angiogenesis.
The meniscal transection (MNX)10 model of OA has been well
characterized in terms of chondropathy and osteophytosis10.
Recently, we have shown in this model that blood vessels also cross
the osteochondral junction11, comparable with observations in the
anterior cruciate ligament transaction model of OA12 and in human
OA7. The MNX model is sensitive to inhibitors of MMPs10 which
have a protective effect on overall cartilage damage as well as
reducing osteophyte formation. However, neither vascular invasion
of the cartilage nor pain behavior were reported in these studies.
Some protective effects are seen for MMP inhibitors in other animal
models of arthritis such as monosodium iodoacetate-induced13,
adjuvant14 and canine surgically-induced arthritides15. Hind paw
weight-bearing assymetry is a measure of pain behavior. The MNXtd. Open access under the Elsevier OA license. 
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were attenuated by a COX -2 inhibitor and gabapentin16.
Associations between OA structural change and pain behavior are
oftenweak, and are incompletely understood, both in animal models
and in human disease17–19. In order to further explore possible
mechanisms linking structural change and pain, we examined
whether the oral administration of a MMP inhibitor would have an
effect on joint pathology, osteochondral vascularity, and pain
behavior, andexploredpossible interactionsbetweenanysucheffects.
Methods
MMP inhibitor characterization
Compound potency and Matrixin family selectivity of M503902
was determined in vitro using Fluorescence Resonance Emission
Transfer (FRET) assays, based on the methodology previously
described20. Brieﬂy, compounds were solubilised in dimethyl
sulphoxide (DMSO, Sigma Aldrich UK) to 10 mM and serially diluted
in assay buffer, (1% (v/v) DMSO, 0.1 M Tris-HCL, 0.1 M NaCl, 10 mM
CaCl2, 005% (v/v) Brij 35) and 50 ml added to 96well Black assay plates
(Cliniplates, Labsystems UK) at ﬁnal concentrations 0.001 nM–
100mM. 25 ml of active enzyme (ﬁnal concentration 0.1–0.7 mg/ml) in
Zinc Calcium buffer, (0.1 M Tris-HCL pH 7.5, 0.1 MNaCl, 0.08 M ZnCl2,
0.05% (w/v) Brij 35, 0.05 M CaCl2) was added to the compound and
incubated for 15 min on a plate shaker at room temperature prior to
addition of substrate at Km, (see Table I for speciﬁc assay substrate).
Plates were incubated in a humidity chamber at 35C for up to 2 h.
Fluorescence was read at time 0 and every 30 min (Spectramax,
Molecular Devices UK) at wavelengths of excitation 328 nm,
emission 393 nm until a suitable window was reached. IC50s were
calculated using an in house automated software package.
Induction of OA
All in vivo procedures were carried out in accordance to the UK
Animals (Scientiﬁc Procedures) Act 1986 and approved by Astra-
Zeneca local ethical review . OA was induced by medial MNX in
male Lewis rats (270 g, Harlan, Bicester, UK), as previously
described14. Brieﬂy, pathology was induced by transecting the
medial collateral ligament and making a full thickness cut through
the meniscus (day 0) of the left knee. For controls, medial collateral
ligament transectionwithout MNX (SHAM) surgery was performed
on the left knee of separate animals.
Treatments
Animals (10 rats per group) were dosed twice daily by oral
gavage with either vehicle (hydroxyprolyl methyl cellulose/tween)Table I
The ability of M503902 to inhibit puriﬁed full-length recombinant human MMPs (expre
(substrate concentration at Km)
Matrixin Peptide substrate
MMP-13 MCA-Pro-Cha-Gly-Nva-Dpa-Ala-Arg-NH2
MMP-1 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-2 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-3 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-7 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-8 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-9 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-12 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-14 MCA-Pro-Cha-Gly-Nva-His-Ala-Dpa-NH2
MMP-19 MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH2
MMPx¼X is the number of matrixin in column 1.or vehicle containing the MMP inhibitor, AstraZeneca M503902
(0.125, 0.5, 2.5 mg/kg from the day prior to surgery, until sacriﬁce at
day 35). The inhibitory proﬁle of M503902 against eleven MMPs is
given in Table I.
Pain behavior
Pain behavior was measured as weight-bearing asymmetry
between operated and contralateral knees. Changes in weight-
bearing asymmetry were assessed at pre surgery (2 days) and at 7,
14, 21, 28 and 35 days post surgery, using an Incapacitance meter
(Linton Instruments, Diss, Norfolk, UK)21,22. This technique
measures the difference in weight bearing between the ipsilateral
operated limb and the contralateral control limb. Rats were placed
in a Perspex container such that each paw rested on a separate
transducer pad that recorded the animals weight distribution over
a period of 3 sec. Each data point is the average of three readings.
The hind paw weight distribution is expressed as the difference in
weight between ipsilateral and contralateral limbs. Weight-bearing
asymmetry was analysed as area under the curve, and possible
associations with histological parameters were determined using
measurements obtained prior to sacriﬁce 35 days after surgery.
Histology
For each animal, skin was removed and the tibiofemoral joints
were isolated by cutting mid-femur and tibia. The joints including
articular surfaces, joint capsule and intra-articular structures were
preserved in 10% neutral buffered formalin for 48–72 h and
subsequently decalciﬁed for 24–36 h in rapid decalciﬁcation ﬂuid
(Surgipath decalciﬁer II – Surgipath Europe Ltd, Peterborough, UK).
Trimmed joint tissues were processed by standard histological
techniques and mounted in wax blocks for sectioning. Coronal
sections (5 mm), through the midpoint of the joint, identiﬁed by the
presence of cruciate ligament insertions, were stained with tolui-
dine blue.
Chondropathy and osteophytosis were evaluated using the
system of Janusz et al.10. In this method cartilage damage was
scored on a scale of 0–5 as follows: 0. Cartilage of normal appear-
ance; 1. Minimal ﬁbrillation, superﬁcial zone only; 2. Mild, extends
to the upper middle zone; 3. Moderate, well into the middle zone;
4. Marked, into the deep zone but not to the tidemark; and 5.
Severe, full thickness degeneration to tidemark. The amount of
cartilage damage was estimated as the proportion of the section of
the medial tibial plateaux involved, 1/3, 2/3 or 3/3 and the cartilage
score multiplied by one, two or three respectively to give a total
chondropathy score. Osteophytosis was scored on a scale of 0–3,
using an eyepiece graticule as follows: 0. No osteophyte present;
1. Mild, <50 mm; 2. Moderate, 50–150 mm; and 3. Severe, >150 mm.ssed in bacculo virus) was determined against synthetic peptide substrates,
M503902
IC50 mean S.E.M (n¼) Ratio (MMPx/MMP13)
0.35 0.05 nM3 1
119 14.5 nM3 340
0.1 nM1 0.29
1.9 nM1 5.4
325 28.9 nM3 929
0.6 nM1 1.71
0.26 0.06 nM5 0.74
0.45 nM1 1.26
3.05 0.67 nM5 8.7
7.2 0.24 nM11 20.6
P.I. Mapp et al. / Osteoarthritis and Cartilage 18 (2010) 593–600 595Osteochondral vascular density was determined by counting the
number of blood vessels crossing the osteochondral junction in the
entire medial tibial plateau of the mid-coronal sections. An arith-
metic mean was determined for at least three replicate sections
from each knee. A geometric mean (þ/95% conﬁdence intervals)
was then calculated for each group of 10 animals.
Measurements were made blinded to diagnostic group or
surgical procedure, and with sections in random order.
Analysis
Data were graphically presented using Prism v 4 (GraphPad, San
Diego CA). Statistical analyses used Statistical Package for the Social
Sciences v.14 (SPSS inc., Chicago, Illinois). Associations are reported
as Spearmann’s rank correlation coefﬁcients. Independence of
associations was determined as partial correlation coefﬁcients.
Differences between groups were sought using 1-way ANOVA
followed by post hoc t-tests with Bonferroni’s corrections on
arithmetic or geometric data, as appropriate. Data are presented in
the text asmean (95% conﬁdence interval) exceptwhere stated, and
graphically as mean (S.E.M.). A two- tailed P< 0.05 was taken to
indicate statistical signiﬁcance.Fig. 1. A). Representative image of the medial tibial plateau of a menisectomised (MNX) anim
loss (arrows). A large osteophyte (circled) has formed at the joint margin. B). Representative
is no evidence of proteoglycan loss or ﬁbrillation of the cartilage surface. The joint marginResults
Effect of an MMP inhibitor on chondropathy, osteophytosis and
blood vessels crossing the osteochondral junction
MNX was associated with the expected OA changes in the
medial tibial plateaux at day 35. These included a loss of surface
integrity, loss of chondrocytes and developing osteophytes
[Fig. 1(A)] SHAM-operated animals did not display evidence of
chondropathy or osteophytosis. [Fig. 1(B)].
TheMMP inhibtor usedwas shown to be an equipotent inhibitor
of MMPs 2, 8, 9,12 and 13 (Table I). Administration of the MMP
inhibitor was associated with a dose-dependent reduction in
chondropathy score [r¼ 0.37, P< 0.01, Fig. 3(A)] with signiﬁcant
reduction of chondropathy at 5 mg/kg/day (4.6, C.I. 2.6–6.5) and at
1 mg/kg/day (4.4, C.I. 2.0–6.7), compared to MNX untreated
controls (8.9, C.I. 5.6–12.1), each P< 0.05.
Osteophytes were not seen in SHAM-operated animals. The
mean osteophyte score for MNX animals was 2.3 (C.I. 1.8–2.8)
compared to SHAM scores of 0.0 (P< 0.0001) [Fig. 3(B)]. Increasing
dose of the MMP inhibitor was not signiﬁcantly associated with
decreasing osteophyte scores (r¼0.29, P> 0.05, Table II).al at 35 days post surgery showing full thickness cartilage ﬁbrillation and proteoglycan
image of the medial tibial plateau of a sham (SHAM) operated animal at 35 days. There
appears normal. Scale bars 100 mm.
Table II
Associations between MMP inhibitor treatment, OA structural severity, osteochon-
dral vascularity and pain behavior
MMP inhibitor
dose
Chondropathy Osteophytosis Osteochondral
vascularity
Chondropathy 0.38*
Osteophytosis 0.29 0.64**
Osteochondral
vascularity
0.89** 0.39* 0.32*
Pain behavior 0.46** 0.38* 0.20 0.33*
Values are Spearman’s correlation coefﬁcients. *P< 0.05, **P< 0.01
P.I. Mapp et al. / Osteoarthritis and Cartilage 18 (2010) 593–600596Blood vessels crossing the osteochondral junction [Figs. 2(A) and
3(C)]weremorenumerous in themedial tibial plateaux35days after
MNX (7.1, C.I 6.1–8.2) than in SHAM-operated animals (1.0, CI 0.6–
1.4) (P< 0.001). The osteochondral vascularity observed in theMNXFig. 2. A). Representative image of the medial tibial plateaux of MNX animal showing loss of
subchondral bone are evident at the osteochondral junction (small arrows). B). Medial tibial
shows no ﬁbrillation but there is some proteoglycan loss as evidence by diminished toluidin
SHAM-operated animal showing intact cartilage and no vascular channels in this section. S
diaphragm to demonstrate blood vessels as refractile structures within channels. Scale baranimals was reduced by treatment with theMMP inhibitor at 5 mg/
kg/day (2.1, CI 1.3–2.8;mean difference 5.0, CI 3.8–6.2) and 1 mg/kg/
day (4.2, CI 3.8–4.6; mean difference 2.9, CI 1.6–4.1, both P< 0.001).
At the highest dose, osteochondral vascularity was similar to the
SHAM-operated controls (mean difference 1.0, CI 0.1–2.3,
P> 0.05). Administration of the inhibitor was associated with
a dose-dependent decrease in the number of vessels crossing the
osteochondral junction (r¼0.89, P< 0.01, Table II).
Effect of MMP inhibitor on pain behavior
Weight-bearing asymmetry was similar in both MNX and
SHAM-operated animals at day 7, persisted in MNX operated, and
normalized in SHAM-operated animals by day 35 (Fig. 4). Area
under the curve (AUC) for weight-bearing asymmetry in SHAM-proteoglycan and cartilage ﬁbrillation (large arrows) vascular channels arising from the
plateu from an MNX animal treated with 5.0 mg/kg/day M503092. The cartilage surface
e blue staining. Fewer vascular channels (small arrow) are seen in treated animals. C).
ections were stained with toluidene blue and imaged with a small diameter substage
s 100 mm.
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Fig. 3. The effect of increasing doses of a MMP inhibitor, in the rat MNX model of OA,
on chondropathy (Panel A), osteophytosis (Panel B) and the number of vessels crossing
the osteochondral junction (Panel C). Treatment with 0.5 and 2.5 mg bid resulted in
signiﬁcant decreases in the chondropathy scores (P< 0.05) and in the number of blood
vessels crossing the osteochondral junction (P< 0.001).There was no signiﬁcant effect
on osteophytosis.
P.I. Mapp et al. / Osteoarthritis and Cartilage 18 (2010) 593–600 597operated animals was 530, CI 322–733, lower than in MNX oper-
ated animals 1488, CI 1137–1839 (P< 0.001). Administration of the
MMP inhibitor was associated with a dose-dependent reduction in
AUC for weight-bearing asymmetry compared with vehicle-treated
MNX controls of 1037, CI 777–1297 (P< 0.05) for 0.25 mg/kg/day,
999, CI 860–1138 (P< 0.05) for 1 mg/kg/day and 760, 576–943
(P< 0.001) for 5 mg/kg/day.Relationship between pathology and pain behavior
Associations between the measured parameters are given in
Table II. Weight-bearing asymmetry was associated with osteo-
chondral vascularity, chondropathy.and although not signifcant
osteophytosis. The reduction of osteochondral vascularity with
increasing dosage of the MMP inhibitor, was independent of the
reduction in chondropathy (partial correlation coefﬁcient 0.88,
P< 0.0001).
Discusssion
OA is a major cause of pain and disability, and is traditionally
characterized as a degenerative condition associated with damage
to articular cartilage and subchondral bone. However, the precise
link between structural changes and pain in OA has been difﬁcult to
establish, with often only weak associations found between
chondropathy or osteophytosis, and symptom severity23,24.
Observational data in human OA have indicated that subchondral
bone or bone marrow lesions25 may be a source of pain26 and we
hypothesise that invasion of the articular cartilage by subchondral
blood vessels may be a key structural change leading to OA pain. In
support of this hypothesis we report here that in the MNX animal
model of OA treated with a MMP inhibitor, that osteochondral
vascularity, as well as chondropathy, was associated with pain
behavior.
MMPs, particularly MMP13, have received attention in OA
research, because of their ability to degrade cartilage matrix
proteins such as type II collagen. Janusz et al10 demonstrated
a reduction in chondropathy following MMP inhibition with an
Matrix Metalloproteinase inhibitor (MMPi) inhibitor, structurally
related to hydroxamic acid (Proctor and Gamble) in a meniscal
injury model of OA. Our result with the AstraZeneca MMP inhibitor,
M503902, supports the importance of MMPs in the development of
chondropathy in this animal model of OA.
Adult articular cartilage is normally an avascular tissue,
although vascular growth occurs at the osteochondral junction in
OA, both in man4,7, and in rats after MNX11. Degradation of the
vascular basement membrane and surrounding extracellular
matrix by MMPs are necessary in order to allow endothelial cells to
migrate and invade surrounding tissue during angiogenesis27.
Reduction of osteochondral vascular density in MNX rats by MMP
inhibitor treatment suggests that MMPs are also necessary for
osteochondral angiogenesis in OA. Inhibition of osteochondral
angiogenesis was observed at a dose of MMP inhibitor which did
not signiﬁcantly affect chondropathy and osteophytosis, andwas, at
least in part, independent of these other aspects of structural
change. MMP inhibition therefore may directly reduce osteochon-
dral angiogenesis. Angiogenesis at the osteochondral junction
requires bone remodelling as well as degradation of cartilage
matrix, as blood vessels are normally separated from the articular
cartilage by the subchondral bone plate. The MMP inhibitor studied
here also inhibited the metallo-gelatinases MMP2 and 9, which are
know to be involved in bone remodelling28. Our data also lead us to
suggest that osteochondral angiogenesis may be dependent on
a restricted range of factors, and therefore may be more susceptible
to inhibition by speciﬁc MMP inhibitors, than are chondropathy or
osteophytosis.
The MNX model of OA is associated with a biphasic pattern of
pain behavior. We observed that early weight-bearing asymmetry
at day 7 affects equally both MNX and SHAM-operated animals.
Pain behavior at this stage is most likely attributable to capsular
damage and synovitis, which also are similar 7 days after either
MNX or SHAM surgery11. Synovitis resolves in SHAM-operated
animals by 28 days after surgery, indicating capsular repair11,
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Fig. 4. Time course showing the effect of increasing doses of a MMP inhibitor on pain behavior, as measured by a difference in weight bearing, in the MNX and SHAM animals.
Vehicle-treated animals continued to show pain behavior but this behavior was dose-dependently decreased by increasing doses of M503092. SHAM animals returned to normal
weight bearing over the course of the experiment. Values for 0.125 mg/kg/bid and 2.5 mg/kg/bid have been offset by 0.5 days to increase the clarity of presentation by preventing
overlap of error bars. Areas under the curve were calculated for the 10 individual animals in each treatment group and a mean with 95% CI’s computed. Differences between groups
were sought with 1-way ANOVA with Bonferroni corrections.
P.I. Mapp et al. / Osteoarthritis and Cartilage 18 (2010) 593–600598whereas MNX animals develop chondropathy, osteophytosis and
increased osteochondral vascularity. Persistent weight-bearing
asymmetry 35 days after MNX, but not after SHAM surgery, indi-
cates that OA structural change rather than capsular damage leads
to pain behavior. Inhibition of weight-bearing asymmetry by the
MMP inhibitor at day 35 inMNX animals, but not 7 days after either
MNXor SHAM operation, leads us to believe that theMMP inhibitor
reduces pain behavior by inhibiting OA structural change, rather
than by reducing early tissue damage or inﬂammation.Effects on chondropathy scores at day 35 were relatively
modest, with chondropathy scores reduced by the highest dose to
approximately half the values observed in vehicle-treated MNX
animals. This contrasts with a near abolition of pain behavior at day
35. Residual chondropathy and osteophytosis therefore do not
necessarily prevent pain relief by structural disease modiﬁcation.
These ﬁndings corroborate clinical data indicating only weak
associations between chondropathy or osteophytosis and reported
pain, and the clinical observation that patients with extensive
P.I. Mapp et al. / Osteoarthritis and Cartilage 18 (2010) 593–600 599structural change on radiographs may report few symptoms18. The
reduction in chondropathy scores is likely due to a direct effect of
the MMPi on proteinases, such as collagenase 3 or MMP9, that can
degrade cartilage matrix proteins. However, an indirect effect
mediated through inhibition of angiogenesis is also possible.
Sensory nerves grow along blood vessels following angio-
genesis in subcutaneous tissues29 and during callus formation30,
and nerves are localised within vascular channels at the osteo-
chondral junction in OA7. Furthermore, increased osteochondral
vascularity is associated with abnormally high hydraulic
conductance through the articular cartilage31 such that osteo-
chondral angiogenesis may expose subchondral nerves to painful
stimuli in OA. We show here that reduced osteochondral angio-
genesis was associated with a marked reduction in pain behavior.
We postulate therefore that inhibition of osteochondral angio-
genesis may be a key component of structural disease modiﬁca-
tion that may improve pain in OA.
In conclusion, herewe show that there is vascular penetration of
articular cartilage in a rat surgical model of OA and that treatment
with an MMP inhibitor is associated with reduction in osteochon-
dral angiogenesis and pain behavior. Osteochondral angiogenesis
may lead to key structural changes that contribute to pain in OA,
raising the possibility that anti-angiogenic agents may reduce OA
pain.
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